Interaction between
Glycerol phenylbutyrate
and
Bictegravir
Moderate
Metabolism
Basic Information
| ID | DDInter833 and DDInter205 |
| Interaction | Coadministration with inducers of CYP450 3A4, particularly those that can also induce uridine diphosphate glucuronosyltransferase (UGT) 1A1, may decrease the plasma concentrations of bictegravir. |
| Management | The potential for diminished pharmacologic effects of bictegravir should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected. |
| References | [1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 [2] "Product Information. Biktarvy (bictegravir/emtricitabine/tenofovir)." Gilead Sciences, Foster City, CA. [3] "Product Information. Viread (tenofovir)." Gilead Sciences, Foster City, CA. |
| Alternative for Glycerol phenylbutyrate |
A16A
|
| Alternative for Bictegravir |
J05A
|
Potential Metabolism Interactions
Substrate-Substrate Interaction：If more than one drug is metabolized by the same CYP, it is possible that its metabolism is inhibited because of the competition between the drugs. That means, it can be useful to lower the dosage of the drugs in the drug-cocktail because they remain longer in the organism than in monotherapy.
Inhibitor-Inhibitor Interaction：Combining two or more inhibitors of one CYP, should be compensated by lowering the dosage of these drugs because the metabolism is reduced and the drugs remain longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.
Inhibitor-Substrate Interaction：Combining drugs that have inhibitory effect and are substrates of one particular CYP, should be compensated by lowering the dosage. They rest longer in the organism than in monotherapy. Not adapting the dosage bears the risk of even more side effects.